NPI 1124211073: Open Payments
NPI 1124211073. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$29 in 2 payments from 2 companies in 2025. Trend: 2023 $202 · 2024 $96 · 2025 $29
Food & beverage: $29
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
Products named: Veozah.
